Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo.
-
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency–Associated Liver Disease With METAVIR Stage F1 Fibrosis
Scottsdale/Phoenix, Ariz.
The purpose of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo.
Contact Us for the Latest Status
Closed for Enrollment
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)
Rochester, Minn.
This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID.
-
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of Pf-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease
Rochester, Minn.
Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
.